180 related articles for article (PubMed ID: 12430147)
1. In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer.
Dimofte A; Zhu TC; Hahn SM; Lustig RA
Lasers Surg Med; 2002; 31(5):305-12. PubMed ID: 12430147
[TBL] [Abstract][Full Text] [Related]
2. Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy.
Zhu TC; Dimofte A; Finlay JC; Stripp D; Busch T; Miles J; Whittington R; Malkowicz SB; Tochner Z; Glatstein E; Hahn SM
Photochem Photobiol; 2005; 81(1):96-105. PubMed ID: 15535736
[TBL] [Abstract][Full Text] [Related]
3. In situ light dosimetry during photodynamic therapy of Barrett's esophagus with 5-aminolevulinic acid.
van Veen RL; Aalders MC; Pasma KL; Siersema PD; Haringsma J; van de Vrie W; Gabeler EE; Robinson DJ; Sterenborg HJ
Lasers Surg Med; 2002; 31(5):299-304. PubMed ID: 12430146
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog.
Ross HM; Smelstoys JA; Davis GJ; Kapatkin AS; Del Piero F; Reineke E; Wang H; Zhu TC; Busch TM; Yodh AG; Hahn SM
J Surg Res; 2006 Oct; 135(2):323-30. PubMed ID: 16650871
[TBL] [Abstract][Full Text] [Related]
5. In vivo optical properties of normal canine prostate at 732 nm using motexafin lutetium-mediated photodynamic therapy.
Zhu TC; Hahn SM; Kapatkin AS; Dimofte A; Rodriguez CE; Vulcan TG; Glatstein E; Hsi RA
Photochem Photobiol; 2003 Jan; 77(1):81-8. PubMed ID: 12856887
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of continuous low-irradiance photodynamic therapy in the treatment of chest wall progression of breast cancer.
Morrison SA; Hill SL; Rogers GS; Graham RA
J Surg Res; 2014 Dec; 192(2):235-41. PubMed ID: 25043529
[TBL] [Abstract][Full Text] [Related]
7. Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light.
Yu G; Durduran T; Zhou C; Zhu TC; Finlay JC; Busch TM; Malkowicz SB; Hahn SM; Yodh AG
Photochem Photobiol; 2006; 82(5):1279-84. PubMed ID: 16696593
[TBL] [Abstract][Full Text] [Related]
8. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.
Verigos K; Stripp DC; Mick R; Zhu TC; Whittington R; Smith D; Dimofte A; Finlay J; Busch TM; Tochner ZA; Malkowicz S; Glatstein E; Hahn SM
J Environ Pathol Toxicol Oncol; 2006; 25(1-2):373-87. PubMed ID: 16566729
[TBL] [Abstract][Full Text] [Related]
9. Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy.
Zhu TC; Finlay JC; Hahn SM
J Photochem Photobiol B; 2005 Jun; 79(3):231-41. PubMed ID: 15896650
[TBL] [Abstract][Full Text] [Related]
10. Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome.
Ericson MB; Sandberg C; Stenquist B; Gudmundson F; Karlsson M; Ros AM; Rosén A; Larkö O; Wennberg AM; Rosdahl I
Br J Dermatol; 2004 Dec; 151(6):1204-12. PubMed ID: 15606516
[TBL] [Abstract][Full Text] [Related]
11. Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer.
Du KL; Mick R; Busch TM; Zhu TC; Finlay JC; Yu G; Yodh AG; Malkowicz SB; Smith D; Whittington R; Stripp D; Hahn SM
Lasers Surg Med; 2006 Jun; 38(5):427-34. PubMed ID: 16788929
[TBL] [Abstract][Full Text] [Related]
12. Performance of a dedicated light delivery and dosimetry device for photodynamic therapy of nasopharyngeal carcinoma: phantom and volunteer experiments.
Nyst HJ; van Veen RL; Tan IB; Peters R; Spaniol S; Robinson DJ; Stewart FA; Levendag PC; Sterenborg HJ
Lasers Surg Med; 2007 Sep; 39(8):647-53. PubMed ID: 17886277
[TBL] [Abstract][Full Text] [Related]
13. Intra-cavity Photodynamic Therapy for malignant tumors of the paranasal sinuses: An in vivo light dosimetry study.
van Doeveren TEM; van Veen RLP; van den Boom F; Tan IB; Schreuder WH; Karakullukçu MB
Photodiagnosis Photodyn Ther; 2020 Dec; 32():101972. PubMed ID: 32835881
[TBL] [Abstract][Full Text] [Related]
14. Light dosimetry for intraperitoneal photodynamic therapy in a murine xenograft model of human epithelial ovarian carcinoma.
Lilge L; Molpus K; Hasan T; Wilson BC
Photochem Photobiol; 1998 Sep; 68(3):281-8. PubMed ID: 9747583
[TBL] [Abstract][Full Text] [Related]
15. Increasing damage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate.
Busch TM; Wang HW; Wileyto EP; Yu G; Bunte RM
Radiat Res; 2010 Sep; 174(3):331-40. PubMed ID: 20726728
[TBL] [Abstract][Full Text] [Related]
16. The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy.
Sitnik TM; Henderson BW
Photochem Photobiol; 1998 Apr; 67(4):462-6. PubMed ID: 9559590
[TBL] [Abstract][Full Text] [Related]
17. Experimental photodynamic therapy for malignant pleural mesothelioma with pegylated mTHPC.
Krueger T; Altermatt HJ; Mettler D; Scholl B; Magnusson L; Ris HB
Lasers Surg Med; 2003; 32(1):61-8. PubMed ID: 12516073
[TBL] [Abstract][Full Text] [Related]
18. Monitoring interstitial m-THPC-PDT in vivo using fluorescence and reflectance spectroscopy.
Kruijt B; van der Ploeg-van den Heuvel A; de Bruijn HS; Sterenborg HJ; Amelink A; Robinson DJ
Lasers Surg Med; 2009 Nov; 41(9):653-64. PubMed ID: 19802884
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of motexafin lutetium-mediated intraperitoneal photodynamic therapy in a canine model.
Griffin GM; Zhu T; Solonenko M; Del Piero F; Kapakin A; Busch TM; Yodh A; Polin G; Bauer T; Fraker D; Hahn SM
Clin Cancer Res; 2001 Feb; 7(2):374-81. PubMed ID: 11234893
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy in the canine prostate using motexafin lutetium.
Hsi RA; Kapatkin A; Strandberg J; Zhu T; Vulcan T; Solonenko M; Rodriguez C; Chang J; Saunders M; Mason N; Hahn S
Clin Cancer Res; 2001 Mar; 7(3):651-60. PubMed ID: 11297261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]